Exclusive distributor Strategic opportunity to expand partnerships with Neopharm as the exclusive Israeli distributor for leading medical manufacturers, enabling access to a curated portfolio for growth in hospitals and clinics.

ALS therapy access Opportunity to initiate co-selling around Amylyx AMX0035 in Israel, Gaza, West Bank and Palestinian Authority, leveraging Neopharm’s established distribution network to accelerate market penetration.

Licensing & launches Neopharm’s history of licensing and launching new medical products (e.g., UroGen Jelmyto, TopGum partnerships) signals readiness to collaborate on regulatory approval, market access, and product launches for innovative devices.

Gummy & consumer bridging Recent TopGum collaboration suggests potential for consumer-focused or adjacent healthcare product lines, enabling cross-selling of related devices or patient-care solutions to existing channels.

Mid-market focus The company operates with a mid-sized footprint (11-50 employees) and revenue range of 1–10M, indicating a nimble partner capable of flexible pilots, co-marketing, and scalable distribution for niche or high-margin medical devices.